-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

A Discussion of Efficacy and Safety on a Treatment Option for Adults with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Program: Product Theaters
Session: A Discussion of Efficacy and Safety on a Treatment Option for Adults With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Saturday, December 5, 2020, 11:00 AM-12:00 PM

Richa Shah, PharmD

Pfizer, New York, NY

Disclosures: No relevant conflicts of interest to declare.

See more of: A Discussion of Efficacy and Safety on a Treatment Option for Adults With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
See more of: Product Theaters